Oh, the places you’ll go! My many colored serotonin (apologies to Dr. Seuss)

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 311, Issue 5, 2016, Pages H1225-H1233

  Watts, Stephanie W ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

5 HT receptors; Arteries; Blood pressure; Serotonin; Veins

Indexed keywords

SEROTONIN; SEROTONIN RECEPTOR;

BLOOD PRESSURE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR SYSTEM; HISTORY OF MEDICINE; HUMAN; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REFERENCE DATABASE; REVIEW; SCIENCE; ANIMAL; ARTERY; DRUG EFFECTS; HISTORY; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT; VASOCONSTRICTION; VASODILATATION;

ANIMALS; ARTERIES; BLOOD PRESSURE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; HYPERTENSION; RATS; SEROTONIN; VASOCONSTRICTION; VASODILATION;

EID: 84994681874     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00538.2016     Document Type: Review

References (99)

1. Akbar H, Chen NY, Fossen DV, Wallace W. Increased vascular contractile sensitivity to serotonin in spontaneously hypertensive rats is linked with increased turnover of phosphoinositide. Life Sci 45: 577-583, 1989.
2. Alsip NL, Harris PD. Serotonin-induced dilatation of small arterioles is not mediated via endothelium-derived relaxing factor in skeletal muscle. Eur J Pharmacol 229: 117-124, 1992.
3. Altura BM. Sex and estrogens and responsiveness of terminal arterioles to neurohypophyseal hormones and catecholamines. J Pharmacol Exp Ther 193: 403-412, 1975.
4. Alsip NL, Schuschke DA, Miller FN. Microvascular responses in the skeletal muscle of the diabetic rats. J Lab Clin Med 128: 429-437, 1996.
5. Balasubramaniam G, Lee HS, Mah SC. Antihypertensive effect of chronic iv administration of 5-carboxamidotryptamine in spontaneously hypertensive rats. Eur J Pharmacol 237: 207-213, 1993.
6. Balasubramaniam G, Lee HS, Mah SC. 5-carboxamidotryptamine attenuates the development of deoxycorticosterone acetate-salt in rats. Eur J Pharmacol 276: 183-190, 1995.
7. Banes AB, Watts SW. Upregulation of arterial serotonin1B and 2B receptors in DOCA-salt hypertension. Hypertension 39: 394-398, 2002.
8. Barnes NM, Sharp T. A review of central 5-HT receptors and their functions. Neuropharmacology 38: 1083-1152, 1999.
9. Baron A, Riesselmann A, Fregly MJ. Reduction in the elevated blood pressure of Dahl Salt sensitive rats treated chronically with L-5-hydroxytryptophan. Pharmacology 42: 15-22, 1991.
10. Berger M, Gray JA, Roth BL. The expanded biology of serotonin. Annu Rev Med 60: 355-366, 2009.
11. Biondi ML, Marasini B, Bianchi E, Agostini A. Plasma free and intraplatelet serotonin in patients with Raynaud’s phenomenon. Int J Cardiol 19: 335-339, 1988.
12. Brenner B, Harney JT, Ahmed BA, Jeffus BC, Unal R, Mehta JL, Kilic F. Plasma serotonin levels and the platelet serotonin transporter. J Neurochem 102: 206-215, 2007.
13. Breuer J, Georgaraki A, Sieverding L, Baden W, Apitz J. Increased turnover of serotonin in children with pulmonary hypertension secondary to congenital heart disease. Pediatr Cardiol 17: 214-219, 1996.
14. Cade JR, Fregly MJ, Privette M. Effect of tryptophan and 5-hydroxytryptophan on the blood pressure of patients with mild to moderate hypertension. Amino Acids 2: 133-140, 1992.
15. Carrasco G, Cruz MA, Gallardo V, Miguel P, Lagos M, Gonzalez C. Plasma and platelet concentration and platelet uptake of serotonin in normotensive and preeclamptic pregnancies. Life Sci 62: 1323-1332, 1988.
16. Castejon AM, Paez X, Hernandez L, Cubeddu LX. Use of intravenous microdialysis to monitor changes in serotonin release and metabolism induced by cisplatin in cancer patients: comparative effects of granisetron and ondansetron. J Pharmacol Exp Ther 291: 960-966, 1999.
17. Centurion D, Glusa E, Sanchez-Lopez A, Valdivia LF, Saxena PR, Villalon CM. 5-HT7, but not 5-HT2B, receptors mediate hypotension in vagosympathetcomized rats. Eur J Pharmacol 19: 239-242, 2004.
18. Chand N. 5-Hydroxytryptamine induces relaxation of goat pulmonary veins: evidence for the noninvolvement of M and D-tryptamine receptors. Br J Pharmacol 72: 233-237, 1981.
19. Cocks TM, Arnold PJ. 5-Hydroxytryptamine (5-HT) mediates potent relaxation in the sheep isolated pulmonary vein via activation of 5-HT4 receptors. Br J Pharmacol 107: 591-596, 1992.
20. Cohen ML, Fuller RW, Kurz KD. Evidence that blood pressure reduction by serotonin antagonists is related to alpha receptor blockade in spontaneously hypertensive rats. Hypertension 5: 676-681, 1983.
21. Cohen ML, Fuller RW, Kurz KD. LY53857, a selective and potent serotonergic (5-HT2) receptor antagonist, does not lower blood pressure in the spontaneously hypertensive rat. J Pharmacol Exp Ther 227: 327-332, 1983.
22. Darios ES, Barman SM, Orer HS, Morrison SF, Davis RP, Seitz BM, Burnett R, Watts SW. 5-hydroxytryptamine does not reduce sympathetic nerve activity or neuroeffector function in the splanchnic circulation. Eur J Pharmacol 754: 140-147, 2015.
23. Davis RP, Linder AE, Watts SW. Lack of serotonin transporter (SERT) reduces the ability of 5-hydroxytryptamine to lower blood pressure. Naunyn Schmiedebergs Arch Pharmacol 383: 543-546, 2011.
24. Davis RP, Pattison J, Thompson JM, Tiniakov R, Scrogin KE, Watts SW. 5-hydroxytryptamine (5-HT) reduces total peripheral resistance during chronic infusion: direct arterial mesenteric relaxation is not involved. BMC Pharmacol 12: 4, 2012.
25. Davis RP, Szasz T, Garver H, Burnett R, Tykocki NR, Watts SW. One-month serotonin infusion results in a prolonged fall in blood pressure in the deoxycorticosterone acetate (DOCA) salt hypertensive rat. ACS Chem Neurosci 4: 141-148, 2013.
26. De Vries P, De Visser PA, Heiligers JP, Villalón CM, Saxena PR. Changes in systemic and regional haemodynamics during 5-HT7 receptor mediated depressor responses in rats. Naunyn Schmiedebergs Arch Pharmacol 359: 331-338, 1999.
27. Diaz J, Ni W, King A, Fink GD, Watts SW. 5-hydroxytryptamine lowers blood pressure in normotensive and hypertensive rats. J Pharmacol Exp Ther 325: 1031-1038, 2008.
28. Ding XR, Stier CT, Itskovitz HD. Serotonin and 5-hydroxytryptophan on blood pressure and renal blood flow in anesthetized rats. Am J Med Sci 297: 290-293, 1989.
29. Doggrell SA. The role of 5-HT on the cardiovascular and renal systems and the clinical potential of 5-HT modulation. Expert Opin Investig Drugs 12: 805-823, 2003.
30. Echizen H, Freed CR. Long-term infusion of L-5-hydroxytryptophan increases brain serotonin turnover and decreases blood pressure in normotensive rats. J Pharmacol Exp Ther 220: 579-584, 1981.
31. Ellis ES, Byrne C, Murphy OE, Tilford NS, Baxter GS. Mediation by 5-hydroxytryptamine2B receptors of endothelium-dependent relaxation in rat jugular vein. Br J Pharmacol 114: 400-404, 1995.
32. Erspamer V, Asero B. Identification of enteramine, the specific hormone of the enterochromaffin cell system, as 5-hydroxytryptamine. Nature 169: 800-801, 1952.
33. Erspamer V, Vialli M. Richerche sul secreto delle cellule enterocromaffini. Boll d Soc Med-chir Pavia 51: 357-363, 1937.
34. Fastier FN, Waal H. The antidiuretic action of 5-hydroxytryptamine in cats in relation to the production of certain chemoreflexes. Br J Pharmacol Chemother 12: 484-488, 1957.
35. Fetkovska N, Amstein R, Ferracin F, Regenass M, Buhler FR, Pletscher A. 5-hydroxytryptamine kinetics and activation of blood platelets in patients with essential hypertension. Hypertension 15: 267-273, 1990.
36. Fetkovska N, Pletscher A, Ferracin F, Amstein R, Buhler FR. Impaired uptake of 5-hydroxytryptamine in platelet in essential hypertension: clinical relevance. Cardiovasc Drugs Ther 4, Suppl 1: 105-109, 1990.
37. Feuerstein TJ. Presynaptic receptors for dopamine, histamine and serotonin. Hand Exp Pharmacol 184: 289-338, 2008.
38. Fink GD. Arthur C Corcoran Memorial Lecture: sympathetic activity, vascular capacitance, and long-term regulation of arterial pressure. Hypertension 53: 307-312, 2009.
39. Fregly MJ, Lockley OE, Sumners C. Chronic treatment with L-5-hydroxytryptophan prevents the development of DOCA-salt induced hypertension in rats. J Hypertens 5: 621-628, 1987.
40. Gellynck E, Heyninck K, Andressen KW, Haegeman G, Levy FO, Vanhoenacker P, Van Craenenbroeck K. The serotonin 5-HT7 receptors: two decades of research. Exp Brain Res 230: 555-568, 2013.
41. Gothert M, Molderings GJ, Fink K, Schlicker E. Heterogeneity of presynaptic serotonin receptors on sympathetic neurons in blood vessels. Blood Vessels 28: 11-18, 1991.
42. Gradin K, Pettersson A, Hedner T, Persson B. Chronic 5-HT2 receptor blockade with ritanserin does not reduce blood pressure in the spontaneously hypertensive rat. J Neural Transm 64: 145-149, 1985.
43. Gujrati VR, Goyal A, Gaur SP, Singh N, Shanker K, Chandravati. Relevance of platelet serotonergic mechanism in pregnancy induced hypertension. Life Sci 55: 327-335, 1994.
44. Gupta P. An endothelial 5-HT receptor that mediates relaxation in guinea-pig isolated jugular vein resembles the 5-HT1D receptor. Br J Pharmacol 108: 703-709, 1982.
45. Hagan JJ, Price GW, Jeffrey P, Deeks NJ, Stean T, Piper D, Smith MI, Upton N, Medhurst AD, Middlemiss DN, Riley GJ, Lovell PJ, Bromidge SM, Thomas DR. Characterization of SB-269970-A, a selective 5-HT7 receptor antagonist. Br J Pharmacol 130: 539-548, 2000.
46. Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 71: 533-554, 2002.
47. Hutri-Kahonen N, Kahonen M, Wu X, Sand J, Nordback I, Taurio J, Porsti I. Control of vascular tone in isolated mesenteric arterial segments from hypertensive patients. Br J Pharmacol 127: 1735-1743, 1999.
48. Ishida T, Kawashima S, Hirata K, Yokoyama M. Nitric oxide is produced via 5-HT1B and 5-HT2B receptor activation in human coronary artery endothelial cells. Kobe J Med Sci 44: 51-63, 1998.
49. Ishine T, Bouchelet I, Hamel E, Lee TJ. Serotonin 5-HT(7) receptors mediate relaxation of porcine pial veins. Am J Physiol Heart Circ Physiol 278: H907-H912, 2000.
50. Itskovitz HD, Werber JL, Sheridan AM, Brewer TF, Stier CT. 5-hydroxytryptophan and carbidopa in spontaneously hypertensive rats. J Hypertens 7: 311-315, 1989.
51. Jelen I, Fananapazir L, Brawford TB. The possible relation between late pregnancy hypertension and 5-hydroxytryptamine levels in maternal blood. Br J Obstetric Gynecol 86: 468-471, 1979.
52. Kamal LA, Quan-Bui KHL, Meyer P. Decreased uptake of 3H serotonin and endogenous content of serotonin in blood platelets in hypertensive patients. Hypertension 6: 568-574, 1984.
53. Kaumann AJ, Levy FO. 5-Hydroxytryptamine receptors in the human cardiovascular system. Pharmacol Ther 111: 674-706, 2006.
54. Kema IP, Meijer WG, Metborg G, Ooms B, Willemse PH, deVries EG. Profiling of tryptophan-related plasma indoles in patients with cardinoid tumors by automated, on-line, solid-phase extraction and HPLC with fluorescence detection. Clin Chem 47: 1811-1820, 2001.
55. Koch CA, Lasho TL, Tefferi A. Platelet-rich plasma serotonin levels in chronic myeloproliferative disorders: evaluation of diagnostic use and comparison with the neutrophil PRV-1 assay. Br J Haematol 127: 34-39, 2004.
56. Krobert KA, Bach T, Syversveen T, Kvingedal AM, Levy FO. The cloned human 5-HT7 receptor splice variants: a comparative characterization of their pharmacology, function and distribution. Naunyn Schmiedebergs Arch Pharmacol 363: 620-632, 2001.
57. Leung E, Walsh LK, Pulida-Rios MT, Eglen RM. Characterization of putative 5-ht7 receptors mediating direct relaxation in Cynomolgus monkey isolated jugular vein. Br J Pharmacol 117: 926-930, 1996.
58. Linder AE, Beggs KM, Burnett RJ, Watts SW. Body distribution of infused serotonin in rats. Clin Exp Pharmacol Physiol 36: 599-601, 2009.
59. Linder AE, Ni W, Szasz T, Burnett R, Diaz J, Geddes TJ, Kuhn DM, Watts SW. A serotonergic system in veins: serotonin transporter-independent uptake. J Pharmacol Exp Ther 325: 714-722, 2008.
60. McDuffie JE, Coaxum SD, Maleque MA. 5-hydroxytryptamine evokes endothelial nitric oxide synthase activation in bovine aortic endothelial cell cultures. Proc Soc Exp Biol Med 221: 386-390, 1999.
61. McGregor DD, Smirk FH. Vascular responses to 5-hydroxytryptamine in genetic and renal hypertensive rats. Am J Physiol 219: 687-690, 1970.
62. Molderings GJ, Werner K, Likungu J, Gothert M. Inhibition of noradrenaline release from the sympathetic nerves of the human saphenous vein via presynaptic 5-HT receptors similar to the 5-HT1D subtype. Naunyn Schmiedebergs Arch Pharmacol 342: 371-377, 1990.
63. Monaghan PJ, Brown HA, Houghton LE, Keevil BG. Measurement of serotonin in platelet depleted plasma by liquid chromatography tandemmass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 877: 2163-2167, 2009.
64. Monti JM, Jantos H. The role of serotonin 5-HT7 receptor in regulating sleep and wakefulness. Rev Neurosci 25: 429-437, 2014.
65. Moran A, Restrepo B, Vega A, de Urbina O, Garcia M, Martin ML, San Roman L. Pharmacological profile of 5-hydroxytyptamine-induced inhibition on the pressor effect elicited by sympathetic stimulation in long term diabetic pithed rats. Eur J Pharmacol 643: 70-77, 2010.
66. Ni W, Geddes TJ, Priestly JR, Szasz T, Kuhn DM, Watts SW. The existence of a local 5-hydroxytryptaminergic system in peripheral arteries. Br J Pharmacol 154: 663-674, 2008.
67. Page IH, McCubbin JW. The variable arterial pressure response to serotonin in laboratory animals and man. Circ Res 1: 354-362, 1953a.
68. Page IH, McCubbin JW. Modification of vascular responses to serotonin by drugs. Am J Physiol 174: 436-440, 1953b.
69. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 57: 1076-1080, 2011.
70. Pimenta E, Calhoun DA. Resistant hypertension: incidence, prevalence and prognosis. Circulation 125: 1594-1596, 2012.
71. Ramage AG, Villalon CM. 5-Hydroxytryptamine and cardiovascular regulation. Trends Pharmacol Sci 29: 472-481, 2008.
72. Rapport MM, Green AA, Page IH. Serum vasoconstrictor (serotonin). IV. Isolation and characterization. J Biol Chem 176: 1243-1251, 1948.
73. Roberts AJ, Hedlund PB. The 5-HT7 receptor in learning and memory. Hippocampus 22: 762-771, 2012.
74. Ruat M, Traiffort E, Leurs R, Tardivel-Lacombe J, Diaz J, Aarrano JM, Schwartz JC. Molecular cloning, characterization and localization of a high-affinity serotonin receptor (5-HT7) activating cAMP formation. Proc Natl Acad Sci USA 90: 8547-8551, 1993.
75. Rudolph AM, Paul MH. Pulmonary and systemic vascular response to continuous infusion of 5-hydroxytryptamine (serotonin) in the dog. Am J Physiol 189: 263-268, 1957.
76. Russell A, Banes A, Berlin H, Fink GD, Watts SW. 5-Hydroxytryptamine2B receptor function is enhanced in the N_-nitro-Larginine hypertensive rat. J Pharmacol Exp Ther 303: 179-187, 2002.
77. Schuschke DA, Joshua IG, Miller FN. Comparison of early microcirculatory and aortic changes in hypercholesterolemic rats. Arterioscler Thromb Vasc Biol 11: 154-160, 1991.
78. Seitz BM, Watts SW. Serotonin-induced hypotension is mediated by a decrease in intestinal vascular resistance. Pharmacologia 5: 50-54, 2014.
79. Seitz BM, Krieger-Burke T, Fink GD, Watts SW. Serial measurements of splanchnic vein diameters in rats using high frequency ultrasound, Front Pharmacol 7: 116, 2016.
80. Selke FW, Dai HB. Responses of porcine epicardial venules to neurohumoral substances. Cardiovasc Res 27: 1326-1332, 1993.
81. Selke FW, Wang SY, Friedman M, Harada K, Edelman ER, Grossman W, Simons M. Basic FGF enhances endothelium-dependent relaxation of the collateral perfused coronary microcirculation. Am J Physiol Heart Circ Physiol 267: H1303-H1311, 1994.
82. Struyker-Boudier HA, le Noble JL, Le Noble FA, Messing MW, van Essen H. Hypertension, the microcirculation and serotonin. Clin Physiol Biochem 8S3: 28-39, 1990.
83. Sumner MJ, Feniuk W, Humphrey PP. Further characterization of the 5-HT receptor mediating vascular relaxation and elevation of cyclic AMP in porcine isolated vena cava. Br J Pharmacol 97: 292-300, 1989.
84. Takahashi R, Sakai T, Furuyama Y, Kondo Y, Inoue CN, Onuma S, Inuma K. The vasocontractive action of norepinephrine and serotonin in deep arterioles of rat cerebral gray matter. Tohoku J Exp Med 190: 129-142, 2000.
85. Tan T, Watts SW, Davis RP. Drug delivery, enabling technology for drug discovery and development. IPRECIO micro infusion pump: programmable, refillable and implantable. Front Pharmacol 2: 44, 2011.
86. Terrón JA. Role of 5-ht7 receptors in the long-lasting hypotensive response induced by 5-hydroxytryptamine in the rat. Br J Pharmacol 121: 563-571, 1997.
87. Thakali K, Fink GD, Watts SW. Arteries and veins desensitize differently to endothelin. J Cardiovasc Pharmacol 43: 387-393, 2004.
88. Thompson LP, Webb RC. Vascular responsiveness to serotonin metabolites in mineralocorticoid hypertension. Hypertension 19: 277-281, 1987.
89. Topsakal R, Kalay N, Gunturk EE, Dogan A, Inanc MT, Kaya MG, Ergin A, Yarlioglues M. The relation between serotonin levels and insufficient blood pressure decrease during night-time in hypertensive patients. Blood Press 18: 367-371, 2009.
90. Trevethick MA, Feniuk W, Humphrey PP. 5-hydroxytryptamine-induced relaxation of neonatal porcine vena cava in vitro. Life Sci 35: 477-486, 1984.
91. Tsuru H, Nakai S, Uchiyama T, Teranishi Y. Endothelium-independent relaxant effect of 5-hydroxytryptamine (5-HT) on the isolated rabbit facial vein. J Smooth Muscle Res 34: 101-110, 1998.
92. Vanhoutte P, Amery A, Birkenhager W, Breckenridge A, Buhler F, Distler A, Dormandy J, Doyle A, Frohlich E, Hansooon L, Hedner T, Hollenberg N, Jensen HE, Lund-Johansen P, Meyer Pl Opie L, Robertson I, Safar M, Schalekamp M, Symoens J, Trap-Jensen J, Zanchetti A. Serotoninergic mechanisms in hypertension. Focus on the effects of ketanserin. Hypertension 11: 11-133, 1988.
93. Watts SW. 5-HT in systemic hypertension: foe, friend or fantasy? Clin Sci 108: 399-412, 2005.
94. Watts SW, Darios ES, Seitz BM, Thompson JM. 5-HT is a potent relaxant in rat superior mesenteric veins. Pharmacol Res Perspect 3: e00103, 2015.
95. Watts SW, Morrison SF, Davis RP, Barman SM. Serotonin and blood pressure regulation. Pharmacol Rev 64: 359-388, 2012.
96. Webb RC, Schreur KD, Papadopoulos SM. Oscillatory contractions in vertebral arteries from hypertensive subjects. Clin Physiol 12: 69-77, 1992.
97. Whitaker-Azmitia P. The discovery of serotonin and its role in neuroscience. Neuropsychopharmacology 21: 2S-8S, 1999.
98. Wilmoth FR, Harris PD, Miller FN. Differential serotonin responses in the skeletal muscle microcirculation. Life Sci 34: 1135-1142, 1984.
99. Zhang L, Dyer DC, Fiscus RR, Grujic Z, Wang X. 5-Hydroxytryptamine induces endothelium-independent relaxations of sheep pulmonary vein: role of cyclic nucleotide. Eur J Pharmacol 280: 335-337, 1995.